| Funding
EISS has three sources of funding: the European Commission (EC), national governments and industry.
EISS has been funded by national governments since 1996 (when the project began) and has received funding from the EC since November 1999. It started receiving funding from industry in September 2000 (GlaxoSmithKline and F. Hofmann-La Roche Ltd. (Switzerland) from September 2000 to December 2002, F. Hofmann-La Roche Ltd. (Switzerland) and Sanofi Pasteur from January 2003 to December 2004).
During the 2000-2001, 2001-2002 and 2002-2003 influenza seasons, the contribution of the EC was roughly 50% of the total EISS budget, the contribution of national governments was around 30% and the contribution of industry was about 20%.
During the 2003-2004, 2004-2005 and 2005-2006 influenza seasons, the contribution of the EC was roughly 42% of the total EISS budget, the contribution of national governments was around 52% and the contribution of industry was about 6%.
EISS uses the following formula to separate EC/national government funding from industry funding:
EC/national government funding:
|
All projects that concern the ongoing running of the surveillance scheme, the EISS website, the annual meetings and the harmonisation and standardisation projects (e.g. the quality control studies).
|
Industry funding:
|
EISS has a strict "code-of-conduct" concerning the influence of industry on its activities and publications, including those on its website. Industry is not involved in the management structure of EISS (industry has an observer status at its annual meetings) or in the preparation of EISS documents, reports and publications. |
|
Last updated: 11 April 2006
|
